Status:
UNKNOWN
Metanx Effects on Nerve Fiber Density in Neuropathic Diabetics
Lead Sponsor:
St. Luke's Hospital and Health Network, Pennsylvania
Collaborating Sponsors:
Goldfarb Foundation
Pamlab, L.L.C.
Conditions:
Diabetes
Peripheral Neuropathy
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This study focuses on the use of Metanx® as the sole treatment for improving and reversing nerve damage in type 2 diabetic patients with peripheral neuropathy. There will be two equal study groups enr...
Eligibility Criteria
Inclusion
- Type 2 Diabetics
- Pre-diabetics
- Symptoms of peripheral neuropathy
Exclusion
- Pregnancy
- Under age 18
- HIV (+)
Key Trial Info
Start Date :
December 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT01503892
Start Date
December 1 2011
Last Update
July 17 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St. Luke's Hospital and Health Network
Bethlehem, Pennsylvania, United States, 18015